Morgan Stanley Abb Vie Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Abb Vie Inc. stock. As of the latest transaction made, Morgan Stanley holds 38,716,851 shares of ABBV stock, worth $6.97 Billion. This represents 0.56% of its overall portfolio holdings.

Number of Shares

38,716,851

Previous 37,243,678 3.96%

Holding current value

$6.97 Billion

Previous $6.39 Billion 19.69%

% of portfolio

0.56%

Previous 0.5%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$163.84 - $199.33 $241 Million - $294 Million	1,473,173 Added 3.96%	38,716,851 $7.65 Billion
Q2 2024 Oct 17, 2024	BUY	$154.79 - $180.76 $321 Million - $375 Million	2,071,989 Added 5.89%	37,243,678 $6.39 Billion
Q2 2024 Aug 14, 2024	BUY	$154.79 - $180.76 $321 Million - $375 Million	2,071,989 Added 5.89%	37,243,678 $6.39 Billion
Q1 2024 Oct 17, 2024	SELL	$159.82 - $182.1 $331 Million - $377 Million	-2,071,989 Reduced 5.56%	35,171,689 $6.4 Billion
Q1 2024 Aug 16, 2024	BUY	$159.82 - $182.1 $179 Million - $204 Million	1,119,154 Added 3.29%	35,171,689 $6.4 Billion
Q1 2024 May 15, 2024	BUY	$159.82 - $182.1 $179 Million - $204 Million	1,119,154 Added 3.29%	35,171,689 $6.4 Billion
Q4 2023 Aug 16, 2024	SELL	$137.6 - $154.97 $439 Million - $495 Million	-3,191,143 Reduced 8.57%	34,052,535 $5.28 Billion
Q4 2023 Feb 13, 2024	BUY	$137.6 - $154.97 $258 Million - $291 Million	1,877,008 Added 5.83%	34,052,535 $5.28 Billion
Q3 2023 Nov 15, 2023	BUY	$133.59 - $154.65 $122 Million - $141 Million	914,485 Added 2.93%	32,175,527 $4.8 Billion
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $22.1 Million - $27.5 Million	-166,952 Reduced 0.53%	31,261,042 $4.21 Billion
Q1 2023 May 15, 2023	SELL	$144.61 - $166.54 $20.8 Million - $23.9 Million	-143,756 Reduced 0.46%	31,427,994 $5.01 Billion
Q4 2022 Feb 14, 2023	BUY	$138.31 - $165.87 $662 Million - $794 Million	4,785,277 Added 17.86%	31,571,750 $5.11 Billion
Q3 2022 Nov 14, 2022	BUY	$134.21 - $153.93 $95.4 Million - $109 Million	710,939 Added 2.73%	26,786,473 $3.6 Billion
Q2 2022 Oct 27, 2022	BUY	$137.62 - $174.96 $990 Million - $1.26 Billion	7,193,804 Added 38.1%	26,075,534 $3.99 Billion
Q2 2022 Aug 15, 2022	BUY	$137.62 - $174.96 $990 Million - $1.26 Billion	7,193,804 Added 38.1%	26,075,534 $3.99 Billion
Q1 2022 Oct 27, 2022	SELL	$131.98 - $163.75 $949 Million - $1.18 Billion	-7,193,804 Reduced 27.59%	18,881,730 $3.06 Billion
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $64.6 Million - $80.1 Million	-489,258 Reduced 2.53%	18,881,730 $3.06 Billion
Q4 2021 Feb 14, 2022	BUY	$107.43 - $135.93 $41.3 Million - $52.3 Million	384,646 Added 2.03%	19,370,988 $2.62 Billion
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $2.02 Billion - $2.29 Billion	18,986,342 New	18,986,342 $2.05 Billion

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account